alexa Abstract | Serum MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in multiple sclerosis clinical subtypes and their diagnostic value in the progressive disease course.

Biomedical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Abstract

In multiple sclerosis (MS), a group of matrix metalloproteinases (MMPs) and their natural tissue inhibitors of metalloproteinases (TIMPs) may play a role in preventing tissue damage. The aim of this study was to determine the correlation between the MMP-9, MMP-2, TIMP- 1, and TIMP-2 serum levels and the possible relationship to the type, severity, and progressive course of MS. Eighty-nine patients and 22 healthy volunteers were enrolled in the study. The MS patients were grouped as follows: 35 relapsing-remitting patients with shortdisease- duration (RRMS-SDD) (≤5 years), 23 patients with longer-disease-duration (RRMSLDD) (≥10 years), 21 secondary progressive patients (SPMS), 6 progressive relapsing patients (PRMS) and 4 primary progressive patients (PPMS). Serum levels were analysed by ELISA. Compared with the Control Group, the TIMP-1 serum levels (ng/ml) increased [Group I (RRMS-SDD), 2242.2; Group II (RRMS-LDD), 3108.3; Group III (SPMS), 3108.3; Group IV (PRMS), 3552.3; Group V (PPMS), 2068.6; and Group VI (control group), 1554.9] (p<0.01), and the MMP-9/TIMP-1 ratios decreased [Group I, 0.074; Group II, 0.055; Group III, 0.043; Group IV, 0.028; Group V, 0.116; and Group VI, 0.107] (p<0.05) in all patient groups except the PPMS group. We re-classified the patients to reflect the progressive disease course as non-progressive (all RRMS) and progressive (PPMS, SPMS, and PRMS) groups. Compared with the control group, we again found an increase in TIMP-1 serum levels (ng/ml) [Groups I-II (RRMS=SDD and LDD), 2726.6; Groups III-IV-V (SPMS, PRMS, and PPMS), 3100.9; and Group VI (control group), 1554.9] (p<0.001) and a decrease in the MMP-9/TIMP-1 ratios [Groups I-II, 0.064; Groups III-IV-V, 0.046; and Group VI, 0.107] (p<0.01). In our study, the MMP-2, MMP-9, TIMP-2 serum levels and MMP- 2/TIMP-2 ratio were not significantly different between the groups altough reclassification. These results mirror the clinical stability that is related to the disease remission status of our patient sample. Further clinical trials will be necessary to examine potential drug targets to prevent patient attacks involving this dynamic pathophysiologic process of MS.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Bilgehan Atlgan ACAR Zeynep Nee ZTEKN Mehmet Fevzi ZTEKN Trkan ACAR

Keywords

Multiple sclerosis subtypes, Progressive Course, MMP-2, MMP-9, TIMP-1, TIMP-2.

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords